TY - JOUR
T1 - Current Vitamin D status in European and Middle East countries and strategies to prevent Vitamin D deficiency: A position statement of the European Calcified Tissue Society
AU - Lips, Paul
AU - Cashman, Kevin D.
AU - Lamberg-Allardt, Christel
AU - Bischoff-Ferrari, Heike Annette
AU - Obermayer-Pietsch, Barbara
AU - Bianchi, Maria Luisa
AU - Stepan, Jan
AU - Fuleihan, Ghada El-Hajj
AU - Bouillon, Roger
AU - on behalf of the Working Group on Vitamin D of the European Calcified Tissue Society
PY - 2019/4/1
Y1 - 2019/4/1
N2 - Vitamin D deficiency (serum 25-hydroxyvitamin D (25(OH)D) <50 nmol/L or 20 ng/mL) is common in Europe and the Middle East. It occurs in <20% of the population in Northern Europe, in 30–60% in Western, Southern and Eastern Europe and up to 80% in Middle East countries. Severe deficiency (serum 25(OH)D <30 nmol/L or 12 ng/mL) is found in >10% of Europeans. The European Calcified Tissue Society (ECTS) advises that the measurement of serum 25(OH) D be standardized, for example, by the Vitamin D Standardization Program. Risk groups include young children, adolescents, pregnant women, older people (especially the institutionalized) and non-Western immigrants. Consequences of Vitamin D deficiency include mineralization defects and lower bone mineral density causing fractures. Extra-skeletal consequences may be muscle weakness, falls and acute respiratory infection, and are the subject of large ongoing clinical trials. The ECTS advises to improve Vitamin D status by food fortification and the use of Vitamin D supplements in risk groups. Fortification of foods by adding Vitamin D to dairy products, bread and cereals can improve the Vitamin D status of the whole population, but quality assurance monitoring is needed to prevent intoxication. Specific risk groups such as infants and children up to 3 years, pregnant women, older persons and non-Western immigrants should routinely receive Vitamin D supplements. Future research should include genetic studies to better define individual vulnerability for Vitamin D deficiency, and Mendelian randomization studies to address the effect of Vitamin D deficiency on long-term non-skeletal outcomes such as cancer.
AB - Vitamin D deficiency (serum 25-hydroxyvitamin D (25(OH)D) <50 nmol/L or 20 ng/mL) is common in Europe and the Middle East. It occurs in <20% of the population in Northern Europe, in 30–60% in Western, Southern and Eastern Europe and up to 80% in Middle East countries. Severe deficiency (serum 25(OH)D <30 nmol/L or 12 ng/mL) is found in >10% of Europeans. The European Calcified Tissue Society (ECTS) advises that the measurement of serum 25(OH) D be standardized, for example, by the Vitamin D Standardization Program. Risk groups include young children, adolescents, pregnant women, older people (especially the institutionalized) and non-Western immigrants. Consequences of Vitamin D deficiency include mineralization defects and lower bone mineral density causing fractures. Extra-skeletal consequences may be muscle weakness, falls and acute respiratory infection, and are the subject of large ongoing clinical trials. The ECTS advises to improve Vitamin D status by food fortification and the use of Vitamin D supplements in risk groups. Fortification of foods by adding Vitamin D to dairy products, bread and cereals can improve the Vitamin D status of the whole population, but quality assurance monitoring is needed to prevent intoxication. Specific risk groups such as infants and children up to 3 years, pregnant women, older persons and non-Western immigrants should routinely receive Vitamin D supplements. Future research should include genetic studies to better define individual vulnerability for Vitamin D deficiency, and Mendelian randomization studies to address the effect of Vitamin D deficiency on long-term non-skeletal outcomes such as cancer.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85063096942&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30721133
U2 - 10.1530/EJE-18-0736
DO - 10.1530/EJE-18-0736
M3 - Article
C2 - 30721133
VL - 180
SP - P23-P54
JO - European Journal of Endocrinology
JF - European Journal of Endocrinology
SN - 0804-4643
IS - 4
ER -